TST001

DRUG4 trials

Sponsors

Transcenta Therapeutics (Hangzhou) Co., Ltd., Shanghai Zhongshan Hospital, Henan Cancer Hospital

Conditions

Advanced CancerBiliary Tract NeoplasmsGastric CancerGastroesophageal-junction CancerPancreatic Cancer

Phase 1

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruitingNCT04396821

Transcenta Therapeutics (Hangzhou) Co., Ltd.Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer +1

Start: 2020-05-28End: 2027-09-30Target: 150Updated: 2026-09-29

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruitingNCT04495296

Transcenta Therapeutics (Hangzhou) Co., Ltd.Advanced Cancer

Start: 2020-08-13End: 2027-09-30Target: 320Updated: 2026-09-29

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Henan Cancer HospitalGastric Cancer, Gastroesophageal-junction Cancer

Start: 2023-01-01End: 2024-10-01Target: 45Updated: 2022-11-08

Phase 2

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

CompletedNCT05190575

Shanghai Zhongshan HospitalBiliary Tract Neoplasms

Start: 2022-01-14End: 2023-05-06Updated: 2023-07-27

Related Papers

Abstract 2645: Characterization of osemitamab in pancreatic cancer models and patients.

Cancer Research2026-04-03

First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102): Updated results of cohort G from a phase I/IIa study.

Journal of Clinical Oncology2025-05-285 citations

First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): Results of cohort G from a phase I/IIa study.

Journal of Clinical Oncology2024-06-013 citations

Abstract CT132: A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors

Cancer Research2024-04-055 citations

Abstract 3629: Prevalence of claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials

Cancer Research2024-03-22

Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

Journal of Clinical Oncology2023-06-0115 citations

A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.

Journal of Clinical Oncology2023-06-014 citations

TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).

Journal of Clinical Oncology2023-01-243 citations

A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.

Journal of Clinical Oncology2022-06-017 citations

A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2022-01-195 citations